## **Hong Kong Society of Uro-Oncology Uro-Oncology Asia 2022**



Major supporting organization

















**Prof. Andrea Necchi** Associate Professor, Vita-Salute San Raffaele University, Head of Genitourinary Medical Oncology, IRCCS San Raffaele Hospital and

Scientific Institute, Milan, Italy



**Prof. Andrew Armstrong** Professor of Medicine, Surgery, Pharmacology and Cancer Biology, Director of Research, the Duke Cancer Institute Center for Prostate and Urologic Cancers, Divisions of Medical Oncology and Urology, **Duke University, United States** 



**Prof. Bertrand Tombal** Chairman, Department of Surgery, Cliniques Universitaires Saint Luc, Universite Catholique de Louvain, **Belgium** 



**Dr. Hans Hammers** Associate Professor, Internal Medicine, Eugene P. Frenkel, M.D. Scholar in Clinical Medicine, Division of Hematology-Oncology, The University of Texas Southwestern Medical Center, **United States** 



**Dr. Joaquin Mateo** Group Leader, Prostate Cancer Translational Research Group, Vall d'Hebron Institute of Oncology, Medical Oncologist, GU Cancers Division, Vall d'Hebron University Hospital, Barcelona, Spain



**Prof. Kim Nguyen Chi** Medical Oncologist, Vancouver Cancer Centre and Vancouver Prostate Centre, Chief Medical Officer, BC Cancer, Professor, Faculty of Medicine, University of British Columbia, Professor, Faculty of Health Sciences, Simon Fraser University, Canada



**Prof. Piet Ost** Associate professor, Faculty of Medicine and Health Sciences, Ghent University, Belgium













## **URO-ONCOLOGY ASIA 2022 AGENDA**

## **22nd January 2022 (Saturday)**

HK Time (GMT+8)	<b>Topics</b>	Speakers	
13:25-13:30	Welcoming Speech	<b>Dr. Philip Kwong</b> President of Hong Kong Society of Uro-Oncology, Hong Kong	
SESSION 1 (PROSTATE SESSION)			
13:30-14:00	Lecture 1		
14:00-14:30	Lecture 2		
14:30-15:00	Lecture 3: Metastasis-directed therapy for oligometastasis	<b>Prof. Piet Ost</b> Associate Professor, Faculty of Medicine and Health Sciences, Ghent University, Belgium	
15:00-15:30	Lecture 4: Evolving CRPC management with proven agents and emerging options	Prof. Bertrand Tombal Chairman, Department of Surgery, Cliniques Universitaires Saint Luc, Universite Catholique de Louvain, Belgium	
15:30-15:50	Panel discussion and Q&A		
15:50-16:00	BREAK		
SESSION 2 (UROTHELIAL CA SESSION)			
16:00-16:30	Lecture 5: Managing the sequential therapeutic options in advanced urothelial carcinoma	Prof. Andrea Necchi Associate Professor, Vita-Salute San Raffaele University Head of Genitourinary Medical Oncology IRCCS San Raffaele Hospital and Scientific Institute, Milan, Italy	
16:30-17:00	Lecture 6		
17:00-17:20	Panel discussion and Q&A		
17:20-17:30	Closing of day 1		

## 23rd January 2022 (Sunday)

HK Time (GMT+8)	<b>Topics</b>	Speakers	
SESSION 3 (PROSTATE SESSION)			
09:00-09:30	Lecture 7: Liquid biopsy for guiding precision medicine in advanced prostate cancer	<b>Dr. Joaquin Mateo</b> Group Leader, Prostate Cancer Translational Research Group, Vall d'Hebron Institute of Oncology, Medical Oncologist, GU Cancers Division, Vall d'Hebron University Hospital, Barcelona, Spain	
09:30-10:00	Lecture 8: The evolving landscape of mHSPC: The latest perspective	Prof. Andrew Armstrong Professor of Medicine, Surgery, Pharmacology and Cancer Biology, Director of Research, the Duke Cancer Institute Center for Prostate and Urologic Cancers, Divisions of Medical Oncology and Urology, Duke University, United States	
10:00-10:30	Lecture 9: Changing landscape in mHSPC	Prof. Kim Nguyen Chi Medical Oncologist, Vancouver Cancer Centre and Vancouver Prostate Centre, Chief Medical Officer, BC Cancer, Professor, Faculty of Medicine, University of British Columbia, Professor, Faculty of Health Sciences, Simon Fraser University, Canada	
10:30-11:00	Lecture 10		
11:00-11:20	Panel discussion and Q&A		
SESSION 4 (RCC SESSION)			
11:20-11:50	Lecture 11		
11:50-12:20	Lecture 12: Dual immune checkpoint blockade in the treatment of advanced RCC	Dr. Hans Hammers Associate Professor, Internal Medicine, Eugene P. Frenkel, M.D. Scholar in Clinical Medicine, Division of Hematology-Oncology, The University of Texas Southwestern Medical Center, United States	
12:20-12:40	Panel discussion and Q&A		
12:40-12:45	Closing Speech	Dr. Darren Poon Vice-President of Hong Kong Society of Uro-Oncology,	

Hong Kong